Publications

Publications

Comparing efficiency of micro-RNA and mRNA biomarker liberation with microbubble-enhanced ultrasound exposure.

By:
Contributors: Robert Paproski, PhD
Ultrasound Med Biol. 2014 Sep;40(9):2207-16. doi: 10.1016/j.ultrasmedbio.2014.05.005. Epub 2014 Jul 9.

Abstract

Blood biomarkers are potentially powerful diagnostic tools that are limited clinically by low concentrations, the inability to determine biomarker origin and unknown patient baseline. Recently, ultrasound has been shown to liberate proteins and large mRNA biomarkers, overcoming many of these limitations. We have since demonstrated that adding lipid-stabilized microbubbles elevates mRNA concentration an order of magnitude compared with ultrasound without microbubbles, in vitro. Unfortunately the large size of some mRNA molecules may limit efficiency of release and hinder efficacy as an ultrasound-liberated biomarker. We hypothesize that smaller molecules will be released more efficiently with ultrasound than larger molecules. Although investigation of large libraries of biomarkers should be performed to fully validate this hypothesis, we focus on a small subset of mRNA and micro-RNAs. Specifically, we focus on miR-21 (22 base pairs [bp]), which is upregulated in certain forms of cancer, compared with previously investigated mammaglobin mRNA (502 bp). We also report release of micro-RNA miR-155 (22 bp) and housekeeping rRNA S18 (1869 bp). More than 10 million additional miR-21 copies per 100,000 cells are released with ultrasound-microbubble exposure. The low- molecular-weight miR-21 proved to be liberated 50 times more efficiently than high-molecular-weight mammaglobin mRNA, releasing orders of magnitude more miR-21 than mammaglobin mRNA under comparable conditions.

 PubMed

Download PDF

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

APCaRI members participate in the Enbridge Ride to Conquer Cancer

Well, we did it!  Several APCaRI members participated in a 2-day major cycling event called the Enbridge Ride to Conquer Cancer, benefiting the Alberta Cancer Foundation. We cycled 228 kms over 2 days along the majestic Rockies with thousands of other Riders, supported by an amazing team of volunteers. Riding along with 34 members of the Cross Cancer Institute Team, and 1741 riders in total, it was an epic experience! The weather could not have been better, it was sunny, warm and the scenery was amazing.
Most importantly, we raised $7.8M to support cutting edge cancer research in Alberta. We are very thankful for the support we received, which will help us to beat prostate cancer.

If you didn’t get a chance to support one of our riders, please consider contributing to the team’s efforts at our DONATE page.

teamfinish

- John Lewis